Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Eligible for anti-chikungunya vaccination according to french Health Authority (HAS)
• Beneficiary of social security coverage
• Signature of informed consent form
Locations
Other Locations
France
CHU La Réunion
RECRUITING
Saint-denis
Contact Information
Primary
Patrick GERARDIN, MD
patrick.gerardin@chu-reunion.fr
(262) 2 62 35 9435
Backup
Florence LEFEBVRE D'HELLENCOURT
promotion.drci@chu-reunion.fr
+262 262 75 34 71
Time Frame
Start Date: 2025-04-18
Estimated Completion Date: 2026-10
Participants
Target number of participants: 1800
Treatments
Experimental: Vaccinated group
Patients who will be vaccinated with the IXCHIQ vaccine
No_intervention: Non-vaccinated group
Patient who will not be vaccinated
Related Therapeutic Areas
Sponsors
Collaborators: Région La Réunion, ANRS, Emerging Infectious Diseases, Direction Générale de l'offre de Soins (DGOS), ARS La Réunion
Leads: Centre Hospitalier Universitaire de la Réunion